DOI
https://doi.org/10.18849/ve.v7i4.585Abstract
PICO question
Does administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine reduce the severity and / or frequency of some anxiety related behaviours in companion dogs, of at least 8 months of age, when compared with no pharmacological treatment?
Clinical bottom line
Category of research question
Treatment
The number and type of study designs reviewed
Two studies, both randomised, were critically appraised. Each had a placebo control group and the dog's owners were blinded to the treatments
Strength of evidence
Moderate
Outcomes reported
Both studies provide moderate evidence that fluoxetine, when dispensed at 1–2 mg/kg per day by oral administration and not involving a behavioural modification program for the patient, may reduce some behaviours associated with separation anxiety and / or compulsive disorders. Both studies indicate that a reduction in some unwanted behaviours may be observed after 1 week of fluoxetine medication. Both studies recommend that behavioural and environmental modifications are important adjuncts to pharmacologic treatment of dogs with either compulsive disorders or separation anxiety. Both studies also report that some dogs treated with fluoxetine experienced anorexia / decreased appetite and lethargy, although most of these effects were transient
Conclusion
The clinical recommendation is that fluoxetine at 1–2 mg/kg administered orally, once daily, may be beneficial in reducing the severity of some canine anxiety related behaviours
How to apply this evidence in practice
The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.
Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.
References
Chutter, M., Perry, P. & Houpt, K. (2019). Efficacy of fluoxetine for canine behavioral disorders. Journal of Veterinary Behavior. 33, 54–58. DOI: https://doi.org/10.1016/j.jveb.2019.05.006
Crowell-Davis, S. (2006). Benzodiazepines Veterinary Psychopharmacology. Crowell-Davis SL and Murray T. Ames, Iowa, Blackwell Publishing. 34–71.
Flannigan, G. & Dodman, N. H. (2001). Risk factors and behaviors associated with separation anxiety in dogs. Journal of the American Veterinary Medical Association. 219(4), 460–466. DOI: https://doi.org/10.2460/javma.2001.219.460
Gruen, M. E. & Sherman, B. L. (2008). Use of trazodone as an adjunctive agent in the treatment of canine anxiety disorders: 56 cases (1995–2007). Journal of the American Veterinary Medical Association. 233(12), 1902–1907. DOI: https://doi.org/10.2460/javma.233.12.1902
Harvey, N. D., Craigon, P. J., Blythe, S. A., England, G. C. & Asher, L. (2016). Social rearing environment influences dog behavioral development. Journal of Veterinary Behavior. 16, 13–21. DOI: https://doi.org/10.1016/j.jveb.2016.03.004
Hewson, C., Luescher, U. & Ball, R. (1998). Measuring change in the behavioural severity of canine compulsive disorder: the construct validity of categories of change derived from two rating scales. Applied Animal Behaviour Science. 60(1), 55–68. DOI: https://doi.org/10.1016/S0168-1591(98)00145-2
Irimajiri, M., Luescher, A. U., Douglass, G., Robertson-Plouch, C., Zimmermann, A. & Hozak, R. (2009). Randomized, controlled clinical trial of the efficacy of fluoxetine for treatment of compulsive disorders in dogs. Journal of the American Veterinary Medical Association. 235(6), 705–709. DOI: https://doi.org/10.2460/javma.235.6.705
Landsberg, G. M. (2001). Clomipramine--beyond separation anxiety. Journal of the American Animal Hospital Association. 37(4), 313–318. DOI: https://doi.org/10.5326/15473317-37-4-313
Landsberg, G. M., Melese, P., Sherman, B. L., Neilson, J. C., Zimmerman, A. & Clarke, T. P. (2008). Effectiveness of fluoxetine chewable tablets in the treatment of canine separation anxiety. Journal of Veterinary Behavior. 3(1), 12–19. DOI: https://doi.org/10.1016/j.jveb.2007.09.001
Liebowitz, M. R., Turner, S. M., Piacentini, J., Beidel, D. C., Clarvit, S. R., Davies, S. O., Graae, F., Jaffer, M., Lin, S.-H., Sallee, F. R., Schmidt, A. B. & Simpson, H. B. (2002). Fluoxetine in Children and Adolescents With OCD: A Placebo-Controlled Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 41(12), 1431–1438. DOI: https://doi.org/10.1097/00004583-200212000-00014
Overall, K. (2013). Manual of Clinical Behavioral Medicine for Dogs and Cats-E-Book. Elsevier Health Sciences.
Papich, M. (2020). Fluoxetine hydrochloride. Papich Handbook of Veterinary Drugs, Elsevior: 385–387.
Pineda, S., Anzola, B., Ruso, V., Ibáñez, M. & Olivares, Á. (2018). Pharmacological therapy with a combination of alprazolam and fluoxetine and use of the trace element lithium gluconate for treating anxiety disorders and aggression in dogs. Journal of Veterinary Behavior. 28: 30–34. DOI: https://doi.org/10.1016/j.jveb.2018.07.013
Simpson, B. S., Landsberg, G. M., Reisner, I. R., Ciribassi, J. J., Horwitz, D., Houpt, K. A., Kroll, T. L., Luescher, A., Moffat, K. S. & Douglass, G. (2007). Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Veterinary Therapeutics. 8(1), 18.
License
Veterinary Evidence uses the Creative Commons copyright Creative Commons Attribution 4.0 International License. That means users are free to copy and redistribute the material in any medium or format. Remix, transform, and build upon the material for any purpose, even commercially - with the appropriate citation.
Most read articles by the same author(s)
- Katherine Nield, Merran Govendir, Comparison of 0.2 Mg/kg Vs. 1.0 Mg/kg of Oral Meloxicam for Safe and Effective Analgesia in Domestic Rabbits , Veterinary Evidence: Vol. 4 No. 2 (2019): The second issue of 2019
- Chun Fung Wong, Merran Govendir, Can dog appeasing pheromone ameliorate stress behaviours associated with anxiety in mature domestic dogs? , Veterinary Evidence: Vol. 6 No. 4 (2021): The fourth issue of 2021
- Lok Yee Stephanie Wong, Merran Govendir, Comparison of the effect of marine-derived omega-3 fatty acids (n-3 FAs) as an adjunct to a non-steroidal inflammatory drug (NSAID) therapy vs NSAID therapy alone, for dogs with osteoarthritis , Veterinary Evidence: Vol. 7 No. 1 (2022): The first issue of 2022
